Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02554591 · ClinicalTrials.gov registry record
Genomic Landscape of Ceritinib
A clinical trial, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- 6
- Enrollment target
NCT02554591 is a clinical trial that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 6 participants.
The verdict
NCT02554591 was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
The investigators propose to conduct a retrospective study of single agent ceritinib in patients with previously untreated anaplastic lymphoma kinase (ALK) rearranged adenocarcinoma of the lung with the sole purpose of characterizing the genomic landscape before ceritinib and at the time of disease progression.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-09-16 |
| Est. Completion | 2018-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02554591
The ClinicalTrials.gov registry entry for NCT02554591 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02554591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02554591 about?
NCT02554591 is a clinical study titled "Genomic Landscape of Ceritinib". The investigators propose to conduct a retrospective study of single agent ceritinib in patients with previously untreated anaplastic lymphoma kinase (ALK) rearranged adenocarcinoma of the lung with the sole purpose of characterizing the genomic landscape before ceritinib and at the time of disease ...
What is the current status of trial NCT02554591?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2015-09-16. Estimated completion is 2018-02-28.
Who is sponsoring clinical trial NCT02554591?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.